NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Medexus Pharmaceuticals Inc. (MDP.TO) Stock Analysis

Medexus Pharmaceuticals Inc. (MDP.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

MDP.TO

CA$5.06

−CA$0.04 (−0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDP.TO with… →

MDP.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$5.10
Previous Close
CA$5.10
Day's Range
5.04–5.13
52-Week Range
2.51–5.50
Volume
16.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.83
Valuation
Market Cap
CA$159.02M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.54
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.10
Financials (FY)
Revenue (FY)
CA$99.33M−8.31%
Net Income (FY)
−CA$2.39M−206.54%
Profit marginThe share of revenue left as profit after all costs and taxes.
−2.29%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.43M
1-Year Return
+65.90%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
48.73K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDP.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+73.88%
2025−15.90%
2024+40.08%
2023+18.75%
2022−18.43%
2021−62.77%
2020+73.86%
2019−17.92%
2018+12.28%
2017−5.00%
2016 (partial year)+22.45%

As of September 4, 2026.

MDP.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$99.33M−CA$2.39M−2.4%
2024CA$108.33MCA$2.25M2.1%
2023CA$113.05M−CA$214.00K−0.2%
2022CA$108.10MCA$1.22M1.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$99.33MCA$54.41MCA$5.84M−CA$2.39M−2.4%
2024CA$108.33MCA$56.58MCA$11.92MCA$2.25M2.1%
2023CA$113.05MCA$59.51MCA$12.79M−CA$214.00K−0.2%
2022CA$108.10MCA$60.04MCA$8.49MCA$1.22M1.1%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

MDP.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricMDP.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.542.3033% below
Profit margin−2.29%−3.14%0.8 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Medexus Pharmaceuticals Inc. (MDP.TO) at CA$159.02M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 90.

The 52-week range on file runs from CA$2.51 to CA$5.50. The most recent close on file for MDP.TO is CA$5.06, dated September 4, 2026. That is −CA$0.04 (−0.78%) against the previous close. The latest close sits 101.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$99.33M. Against the prior fiscal year total of CA$108.33M, that is a change of −8.31%. The same year closed with a net loss of CA$2.39M. Profit margin runs at −2.29%. That is 0.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.1.

Across the 4 fiscal years on file, revenue moves from CA$108.10M in 2022 to CA$99.33M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.54 times revenue. On price-to-sales that is 32.96% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +65.90%. Measured over 10 years, that is +1.52% a year compounded. Beta against the wider market is reported at 1.84. Daily returns over the trailing 10 years annualize to a volatility of 71.75%.

Growth & Income

The record shows no dividend for MDP.TO.

2026 is still running; the price is +73.88% year to date. The strongest complete calendar year on file is 2020 at +73.86%; the weakest is 2021 at −62.77%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Medexus Pharmaceuticals Inc. (MDP.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Medexus Pharmaceuticals Inc. MDP.TO CA$159.02M —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Medexus Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Visit website →